N,N'-dimethylarginine

Known as: L-ornithine, N(5)-((methylamino)(methylimino)methyl)-, symmetric dimethylarginine, guanidino-N(1),N(2)-dimethylarginine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Asymmetric and symmetric dimethylarginine (ADMA and SDMA, respectively) are toxic, non-proteinogenic amino acids formed by post… (More)
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND & OBJECTIVES Chronic kidney disease (CKD) is characterized by chronic inflammation, considered a nontraditional risk… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
RATIONALE Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor that competes with L-arginine… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The guanidines asymmetric dimethylarginine (ADMA), a marker of endothelial dysfunction, and its counterpart symmetric… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 6
Is this relevant?
2006
2006
Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in… (More)
Is this relevant?
2006
Highly Cited
2005
Highly Cited
2005
The cDNA for PRMT7, a recently discovered human protein-arginine methyltransferase (PRMT), was cloned and expressed in… (More)
Is this relevant?
2005
2005
Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) inhibit production of nitric oxide. The concentration of both… (More)
Is this relevant?
Review
2003
Review
2003
There is abundant evidence that the endothelium plays a crucial role in the maintenance of vascular tone and structure. One of… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), may be related to reduced… (More)
Is this relevant?